Veterans With PTSD Who Quit Cannabis Saw Major Symptom Improvement

Open-label pilot study, N=21 veterans with comorbid PTSD and CUD. Progressive contingency reinforcement payments for abstinence confirmed at weeks 4, 8, and 12. Abstinence defined as THC-COOH ≤50 ng/mL with no self-reported use. PTSD assessed via CAPS-5 (total severity, symptom count, cluster scores). Data collected January 2022 to April 2025.

PTSD is one of the most commonly cited reasons veterans use cannabis, and many advocate for medical cannabis as a PTSD treatment. This study provides the first prospective evidence that quitting cannabis — not starting it — may be what actually reduces PTSD symptoms. The magnitude of improvement (70% reduction in CAPS-5 scores) is clinically remarkable, even considering the small sample.

This directly challenges the narrative supporting cannabis for PTSD. The veteran harm reduction study (RTHC-00267) documented veterans using cannabis to manage trauma symptoms, and the intensive PTSD treatment study (RTHC-00276) examined cannabis use during evidence-based therapy. This abstinence study adds a critical counter-perspective: cannabis may be masking symptoms rather than treating them, and removal of cannabis may allow underlying PTSD treatments to work more effectively.

Very small sample (N=21) in an open-label design without randomization. Self-selection bias: veterans who achieved abstinence may differ from those who didn't in motivation, severity, or other factors. Contingency payments may have influenced adherence rather than reflecting real-world conditions. No long-term follow-up — whether symptom improvement persists is unknown. The study cannot determine whether abstinence caused the improvement or whether both reflect a shared underlying factor.